COMMUNIQUÉS West-GlobeNewswire

ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
12/05/2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to [...]
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
12/05/2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
12/05/2025
Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ET PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company [...]
Transactions in Connection with Share Buy-back Program
12/05/2025
Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital [...]
Brain Cancer Canada Grants McGill University $100,000 to Advance Pediatric Brain Cancer Research
12/05/2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to award a $100,000 pediatric research grant to Dr. Carl Ernst, professor and scientist at McGill University, and his team. The work explores a [...]
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
12/05/2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful [...]
Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment
12/05/2025
DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is [...]
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease
12/05/2025
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease Lille, May 12, 2025 – InBrain [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2025 D’IBA SA
12/05/2025
- MERCREDI 11 JUIN 2025 À 10H00 - Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO » ) des actionnaires d’IBA qui se tiendra le mercredi 11 juin 2025 à 10h00 , pour [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2025 OF IBA SA
12/05/2025
– WEDNESDAY, JUNE 11, 2025, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be held on Wednesday June 11, 2025 at 10:00 A.M., to deliberate on [...]
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
12/05/2025
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated [...]
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
12/05/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025 Männedorf, [...]
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis
12/05/2025
Saint Herblain (France), le 12 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA [...]
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
12/05/2025
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control [...]
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
12/05/2025
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a [...]
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
12/05/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule [...]
Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ
12/05/2025
PARIS and CAMBRIDGE, Mass., 12 mai 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
12/05/2025
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to [...]
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
12/05/2025
The REAL8 trial showed that after 52 weeks, once-weekly Sogroya ® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin ® (somatropin) in children born small for gestational age (SGA) [...]

Pages